Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 241–264 of 310
CD47 Platelets Suppress Aging Inflammation in Centenarians
Centenarians carry genetic and platelet-based mechanisms that suppress age-related inflammation through CD47 expression, which dampens monocyte activation. The LAV-BPIFB4 variant drives this protective effect, and recombinant administration of the protein replicates these benefits in non-carriers, establishing a translatable therapeutic target for inflammaging and cardiovascular disease.
Dog Gene Therapy Shows Early Safety in Aging Trial
Genflow Biosciences reports early safety and survival benefits in its SLAB gene therapy trial in 24 aging beagles, with no adverse events observed at three months. The study represents an emerging model in longevity research: using companion animals as a translational bridge between laboratory studies and human trials, where faster aging enables observation of long-term changes within years rather than decades.
Kidney Regeneration Surgery: Restoring Function, Not Managing Decline
Rokit Healthcare has received clinical approval to begin the first human kidney regeneration surgery using autologous omentum-derived cells combined with AI-assisted 3D bioprinting and robotic surgery, with trials starting July 2026. This represents a shift from chronic kidney disease management toward actual tissue regeneration, with potential to restore organ function rather than manage decline.
Restoring Lysosomal Clearance Targets Parkinson's Root Cause
Researchers identified a protein that restores lysosomal clearance of alpha-synuclein, the pathogenic protein driving Parkinson's disease. This addresses a fundamental breakdown in cellular protein quality control that accelerates neurodegeneration with age.
Senescence at the crossroads of postpartum remodeling and tumorigenesis
Cellular senescence plays a dual role in postpartum mammary gland remodeling—supporting normal tissue reorganization while simultaneously creating conditions that enhance tumor progression when oncogenic events coincide with gland involution. This mechanism reveals how a normally protective cellular state becomes pathogenic under specific developmental and genetic circumstances.
Testing the redox theory of aging under parasitism
Parasitic infection accelerates oxidative stress and aging markers in host organisms, providing empirical support for redox-based aging mechanisms. This finding illuminates how chronic pathogenic burden compounds systemic dysfunction and accelerates cellular deterioration through reactive oxygen species accumulation.
Extracellular matrix: new insights into its role in female reproductive aging and potential therapeutic strategies
The extracellular matrix—the structural scaffold surrounding reproductive tissues—undergoes progressive degradation during female reproductive aging, compromising ovarian function and fertility. Targeting matrix preservation and remodeling represents a mechanistic approach to extending reproductive lifespan and potentially supporting broader aging-related outcomes.
RANKL Inhibition Reverses Bone Loss and Extends Lifespan
RANKL targeting—via genetic deletion or antibody neutralization—reverses bone loss, restores muscle function, and extends lifespan in a mouse model of Hutchinson-Gilford progeria. This suggests RANKL inhibition may address the accelerated tissue degeneration characteristic of this premature aging syndrome.
Engineered fat cells deliver multi-year gene therapies
Remedium Bio secured $10 million in Series A funding to advance gene therapies designed for durable, long-lasting protein production using engineered fat cells as a therapeutic depot. The platform targets chronic diseases across endocrinology, immunology, neurology, musculoskeletal, and cardiometabolic domains with single-injection, adjustable dosing.
Integrin‐Binding Matricellular Protein Fibulin‐5 Maintains Epidermal Stem Cell Heterogeneity During Skin Aging
Fibulin-5, an extracellular matrix protein that declines with age, maintains epidermal stem cell function by activating YAP signaling through integrin binding. Loss of fibulin-5 reproduces age-associated changes in skin stem cell populations, identifying a molecular mechanism linking extracellular environment degradation to cellular aging.
Human cGAS Drives LINE‐1 Transcriptional Activation to Trigger MAVS‐Dependent Cellular Senescence
Human cGAS activates LINE-1 retrotransposon transcription through upregulation of CTCF and RUNX3, triggering cellular senescence via MAVS-dependent RNA sensing. This human-specific pathway reveals a mechanism linking genomic surveillance to accelerated cellular aging, with direct implications for understanding senescence in aging and age-related disease.
Aspen wins official name for Parkinson’s cell therapy candidate
Aspen Neuroscience received WHO and AMA approval for the official name Sasineprocel for its autologous dopaminergic cell therapy derived from patient skin cells. The therapy aims to restore dopamine-producing neurons in Parkinson's disease without immunosuppression, currently in Phase 1/2a trials.
Telomere Shortening Drives Atrial Fibrillation Through VCAM‐1 Mediated Atrial Electrical and Structural Remodeling
Telomere shortening drives atrial fibrillation through VCAM-1 upregulation, which promotes atrial fibrosis and electrical dysfunction. Blocking VCAM-1 reverses these changes and reduces AF susceptibility by 30%, identifying a mechanistic pathway linking cellular aging to arrhythmia risk.
Abinopharm releases AbinoNutra® NMN white paper after FDA reinstatement and clinical evidence
Abinopharm released a white paper on AbinoNutra® NMN following FDA regulatory clarification confirming NMN's legality as a dietary supplement ingredient. A randomized, double-blind clinical trial demonstrated that 60 days of NMN supplementation at doses up to 900 mg increased blood NAD⁺ levels, improved physical performance and endurance, and showed favorable shifts in biological age markers with no serious adverse events.
Pandorum lands $18m to advance ‘programmable regenerative medicine’
Pandorum Technologies closed an $18 million Series B round to advance exosome-based therapies designed to modulate tissue state away from inflammatory and fibrotic conditions toward functional recovery. The platform targets corneal opacity initially, with applications potentially extending across multiple organs affected by inflammatory and degenerative disease.
Single‐Cell Profiling Reveals RAB13+ Endothelial Cells and Profibrotic Mesenchymal Cells in Aged Human Bone Marrow
Single-cell analysis reveals that aging bone marrow undergoes distinct cellular remodeling: endothelial cells develop prothrombotic and mitochondrial dysfunction, while a novel RAB13+ arterial endothelial subset emerges alongside expansion of profibrotic mesenchymal cells. These cellular shifts directly impair the marrow's capacity to support healthy blood cell production and tissue maintenance, establishing specific molecular targets for intervention.
Celularity secures $35m license deal to back longevity strategy
Celularity licensed its placental-derived biomaterials portfolio for up to $35 million in non-dilutive capital, allowing the company to redirect resources toward cell therapies targeting senescence, inflammation, and tissue degeneration. This repositioning reflects a strategic shift from broad biomaterials commercialization to targeted longevity interventions.
RNA Recycling Extends Lifespan
RNASEK, an enzyme that degrades circular RNA accumulation in cells, extends lifespan in model organisms by removing a form of molecular waste that accelerates aging. This identifies a specific degradation pathway central to cellular longevity.
CFTR Protein Blocks Heart Cell Aging Through Calcium Control
CFTR, a protein typically studied for its ion channel function, operates through a secondary mechanism to prevent cardiomyocyte senescence by reducing mitochondrial oxidative stress. The USP45 enzyme stabilizes CFTR through deubiquitination, which enhances calcium regulation and protects heart cells from age-related dysfunction implicated in atrial fibrillation and cardiovascular disease.
Unlimited Bio registers dual gene therapy trial
Unlimited Bio initiated a Phase 1/2a trial combining AAV9-Follistatin and VEGF plasmid gene therapies to address age-related muscle decline, marking the first registered clinical study to combine these two approaches. The dual-therapy strategy targets both muscle growth signaling and vascular support, with safety and functional outcomes tracked over 12 months in adults aged 45 to 75.
Pretzel Therapeutics presents PX578 data supporting POLG disease treatment
PX578, a first-in-class small molecule activator of mitochondrial DNA polymerase gamma, demonstrated preclinical efficacy in restoring mitochondrial DNA levels and cellular energy production across multiple POLG disease models. The compound addresses the underlying genetic defect in mitochondrial DNA depletion syndromes, for which no disease-modifying treatments currently exist.
Engineering longevity with the ZEUGMA hyperbaric chamber
Hyperbaric oxygen therapy, traditionally confined to clinical medicine, is being deployed in performance and longevity settings through chambers like ZEUGMA, which operate at pressures enabling oxygen to dissolve into plasma at concentrations far exceeding atmospheric levels. The mechanism addresses tissue oxygen delivery and cellular repair, though evidence for durable benefits in healthy individuals remains under investigation.
Nuritas brings PeptiStrong clinical momentum to Vitafoods
Nuritas is conducting a 30-day randomized controlled trial comparing PeptiStrong (a fava bean-derived peptide) plus whey protein against whey protein alone in adults aged 60–85, with grip strength as the primary outcome and secondary measures including gait speed, balance, and inflammatory markers. The trial addresses a direct mechanism relevant to aging: preserving muscle function and mass in older populations.
STING Blockade Protects Aging Bone from Marrow Fat Signals
In aging mice, bone marrow fat cells secrete DPP4 and other factors that activate the cGAS–STING pathway in marrow macrophages, producing chronic inflammatory signaling that suppresses bone formation and lowers NAD⁺ in osteoblast progenitors. Silencing STING specifically in macrophages between 12 and 18 months preserved bone density and architecture, increased new bone deposition, and reduced marrow fat accumulation. The work positions innate immune sensing of displaced DNA as an upstream driver of age-related skeletal decline rather than a bystander.